South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Malaysia Central Bank Moves to Support Ringgit Amid Foreign Fund Outflows 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Australia Inflation Cools in May, But Core CPI Keeps RBA Rate Hike Risks Alive 
U.S.-Iran Diplomacy Helps Drive Gasoline Prices Down 15% From May Highs 
New Zealand Fast-Tracks Gold Mining as Industry Revival Gains Momentum 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
Asian Stocks Slide as AI Rally Pauses, South Korean Chipmakers Lead Regional Decline 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
South Korea Remains MSCI Emerging Market Despite Reform Progress 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Bristol Myers Squibb has been sued for $6. 4 billion for allegedly delaying a cancer drug. In the new lawsuit, it was claimed that the American multinational pharmaceutical company headquartered in New York improperly held up the development of a medicine for the treatment of non-Hodgkin's lymphoma.
The allegation against the pharma company
According to Reuters, it was alleged that Bristol Myers Squibb deliberately delayed the development so it can avoid paying $6.4 billion to Celgene Corp. shareholders. Bristol Myers acquired this drug manufacturing company in 2019.
Based on the complaint that was filed at the Manhattan federal court on Thursday, June 3, the company would have owed the said amount if it had received the approval from the U.S. Food and Drug Administration for specified deadlines for three drugs that Celgene had been developing.
In the filing, it was stated that the pharmaceutical company failed to use contractually required "diligent efforts" to get the FDA’s approval for the cancer drug called Breyanzi before the set deadline of Dec. 31, 2020. Now, with no approval before the deadline, the company was excused from paying the sum to Celgene.
It was reported that the lawsuit was filed by the UMB Bank NA, which is acting as a trustee for Celgene’s former shareholders. Bristol-Myers acquired Celgene under a $80.3 billion deal that was signed in November 2019.
Bristol Myers Squibb accused of misconduct
The former shareholders think that Bristol Myers did not exert efforts to beat the deadline when it was supposed to get the FDA’s approval for Breyanzi. They are suspecting that the company did this deliberately to avoid paying them, so they are accusing Bristol Myers of “blatant misconduct,” as per Fierce Pharma.
Finally, the case against Bristol Myers was recorded under 1:21-cv-04897 in the U.S. District Court-Southern New York. The shareholders that were represented by UMB Bank NA sued the pharma firm for breaching the CVR agreement through its failure to exert efforts to secure the needed approval from the FDA.
